Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada. Show more

Location: 322 11th Avenue SW, Calgary, AB, T2R 0C5, Canada | Website: https://oncolyticsbiotech.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

106.1M

52 Wk Range

$0.33 - $1.51

Previous Close

$1.00

Open

$1.01

Volume

308,081

Day Range

$0.99 - $1.04

Enterprise Value

97.97M

Cash

12.35M

Avg Qtr Burn

-6.617M

Insider Ownership

0.00%

Institutional Own.

2.65%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Pelareorep + paclitaxel + avelumab (Bavencio®) Details Breast cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab Details metastatic pancreatic ductal adenocarcinoma (mPDAC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Retifanlimab Details Triple-negative breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + modified FOLFIRINOX +/- atezolizumab Details Metastatic pancreatic cancer (mPDAC)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Atezolizumab (Tecentriq) Details 2L Squamous Cell Carcinoma of Anal Canal (SCAC)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep +/- Atezolizumab Details Cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.